Australian Journal of General Practice
MBBS (Hons), BMedSc (Hons), FRACP, Endocrinologist, Department of Endocrinology, Royal Darwin Hospital, Darwin, NT; Senior Research Officer, Menzies School of Health Research, Charles Darwin University, Darwin, NT
Numerous glucose-lowering medications have been developed in recent years with growing evidence relating to their efficacy and safety.
Sodium–glucose co-transporter-2 inhibitors are becoming a cornerstone of therapy for type 2 diabetes, kidney disease and heart failure.